Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome).
Richard A Hrachovy, James D Frost
https://pubmed.ncbi.nlm.nih.gov/14734931Actively Recruiting
Led by Kullasate Sakpichaisakul · Updated on 2021-08-25
250
Participants Needed
1
Research Sites
26 weeks
Total Duration
Infantile spasms (IS) are seizures linked to a serious brain condition in infants, characterized by specific seizure patterns and developmental delays. Researchers are comparing two treatments to see which better stops spasms and improves brain activity: a combination of vigabatrin with high dose prednisolone versus vigabatrin alone. This trial addresses challenges in treatment availability, especially where ACTH is not accessible, like in Thailand. The study involves two groups. One group receives vigabatrin tablets in doses adjusted by weight, gradually increasing if seizures persist, continued for three months before tapering off over four weeks. The other group receives the same vigabatrin dosing plus high dose prednisolone tablets for one month, starting at 40 mg daily and increasing to 60 mg if needed, then tapered off. The treatments are given orally, and the study compares their effectiveness in stopping spasms. Participants are infants aged 2 to 14 months diagnosed with infantile spasms. Researchers will monitor seizure cessation between days 14 and 42 after treatment starts and assess brain wave activity with EEG at specific intervals. They will also track relapse, adverse reactions, and long-term epilepsy outcomes up to 18 months of age. Caregivers and medical staff will be involved throughout the study duration, which includes follow-up assessments to measure treatment responses and safety.
CONDITIONS
Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 months
Participants receive either combination therapy with vigabatrin and high dose prednisolone for 1 month plus vigabatrin alone for 4 months, or vigabatrin alone for 4 months.
Visits occur throughout the 4-month treatment period according to treatment protocol
Duration - Up to 18 months after treatment ends
Participants are monitored for relapse of spasms, adverse reactions, and epilepsy outcomes up to 18 months after treatment.
Periodic visits for assessments up to 18 months post-treatment
Total: 1 location
1
Queen Sirikit National Institute of Child Health
Ratchathewi, Bangkok, Thailand, 10400
Actively Recruiting
K
Kullasate Sakpichaisakul, MD
S
Sirorat Suwannachote, MD
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Richard A Hrachovy, James D Frost
https://pubmed.ncbi.nlm.nih.gov/14734931P M Jeavons, B D Bower, M Dimitrakoudi
https://pubmed.ncbi.nlm.nih.gov/4515986E Trevathan, C C Murphy, M Yeargin-Allsopp
https://pubmed.ncbi.nlm.nih.gov/10368073R A Hrachovy, J D Frost, P Kellaway
https://pubmed.ncbi.nlm.nih.gov/6539199John M Pellock, Richard Hrachovy, Shlomo Shinnar...
https://pubmed.ncbi.nlm.nih.gov/20608959Andrew L Lux, John P Osborne
https://pubmed.ncbi.nlm.nih.gov/15509243M T Mackay, S K Weiss, T Adams-Webber...
https://pubmed.ncbi.nlm.nih.gov/15159460James W Wheless, Dave F Clarke, Alexis Arzimanoglou...
https://pubmed.ncbi.nlm.nih.gov/18077226Scott T Demarest, Renée A Shellhaas, William D Gaillard...
https://pubmed.ncbi.nlm.nih.gov/29105055Ravindra Arya, Shlomo Shinnar, Tracy A Glauser
https://pubmed.ncbi.nlm.nih.gov/22859699